Bal Pharma Ltd

Bal Pharma Management Change

Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.

Bal Pharma Annual General Meeting

Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.

Bal Pharma Price Movement Clarification

Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.

Bal Pharma Other Announcement

Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.

Bal Pharma Capital Structure Change

Bal Pharma Ltd allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, at ₹84 per warrant. This preferential issue aggregates to ₹8.4 Crore.

Value

₹8.40 Cr

Bal Pharma Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 450.0% YoY

Bal Pharma Ltd reported revenue from operations of ₹88.6 Cr (+34.4% YoY) and net profit of ₹1.1 Cr (+450.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1.1 Cr · +450.0% YoY

Bal Pharma Q4 FY26 Results: Net Profit ₹3.6 Cr, Down 33.3% YoY

Bal Pharma Ltd reported revenue from operations of ₹84.1 Cr (+2.7% YoY) and net profit of ₹3.6 Cr (-33.3% YoY) for Q4 FY26.

Key figure

Net profit ₹3.6 Cr · -33.3% YoY